SNN - Smith & Nephew plc
| Previous Close | 47.85 |
| Open | 47.24 |
| Bid | 31.00 x 800 |
| Ask | 47.90 x 1000 |
| Day's Range | 47.16 - 47.91 |
| 52 Week Range | 37.69 - 50.69 |
| Volume | 557,296 |
| Avg. Volume | 543,700 |
| Market Cap | 20.771B |
| Beta (5Y Monthly) | -0.07 |
| PE Ratio (TTM) | 30.04 |
| EPS (TTM) | 1.59 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.73 (1.52%) |
| Ex-Dividend Date | Oct 02, 2019 |
| 1y Target Est | 52.57 |
- Simply Wall St.
Read This Before Selling Smith & Nephew plc (LON:SN.) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GuruFocus.com
3 High-Performing Securities to Consider
Their stock prices have increased faster than the S&P; 500 Continue reading...
- Zacks
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
- Business Wire
A newly published multicentre RCT demonstrates Smith+Nephew PICO◊ single use NPWT as superior to traditional NPWT in reducing wound area, depth and volume in DFUs and VLUs
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is excited to announce the publication of results from a new randomised controlled trial (RCT) demonstrating that the use of PICO◊ Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared with traditional negative pressure wound therapy (tNPWT) in patients with venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).1*
- Business Wire
Clinical trial demonstrated superior wound closure rates with PICO◊ compared to traditional NPWT in lower extremity ulcers1
Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces the publication of a new randomized controlled trial (RCT) which demonstrated that the use of PICO Single Use Negative Pressure Wound Therapy System (sNPWT) significantly reduced wound area, depth and volume compared to traditional negative pressure wound therapy (tNPWT) in patients with lower extremity ulcers.1*
- Simply Wall St.
Do You Like Smith & Nephew plc (LON:SN.) At This P/E Ratio?
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
- Insider Monkey
Here is What Hedge Funds Think About Smith & Nephew plc (SNN)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Simply Wall St.
What Can We Make Of Smith & Nephew plc’s (LON:SN.) High Return On Capital?
Today we'll look at Smith & Nephew plc (LON:SN.) and reflect on its potential as an investment. Specifically, we're...
- Zacks
Smith & Nephew's JOURNEY II UK Knee System Executes Surgeries
The JOURNEY II UK development is expected to provide a major impetus to Smith & Nephew's (SNN) Orthopedics segment.
- Insider Monkey
Hedge Funds Love CoStar Group Inc (CSGP) Way More Than These 3 Stocks
The 700+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
- PR Newswire
Smith+Nephew announces first surgeries using new JOURNEY™ II Unicompartmental Knee System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the completion of the first surgeries utilizing its new JOURNEY II Unicompartmental Knee (UK) System. Built on the heritage of the most clinically successful partial knee,1,2 JOURNEY II UK is designed to help patients rediscover their normal life before they first experienced knee pain.
- Simply Wall St.
Did Changing Sentiment Drive Sunniva's (CNSX:SNN) Share Price Down A Painful 91%?
As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid...
- Zacks
Smith & Nephew's Study Outcomes for REGENETEN Encouraging
Smith & Nephew's (SNN) announces positive study outcomes for REGENETEN.
- PR Newswire
New study shows 96% healing of hard to treat large and massive rotator cuff tears with Smith+Nephew's REGENETEN™ Bioinductive Implant
LONDON , Nov. 19, 2019 /PRNewswire/ -- Smith+Nephew (LSE: SN, NYSE: SNN), the global medical technology business, today announces a new clinical study illustrating the successful treatment of large (3-5cm) ...
- PR Newswire
Smith+Nephew launches industry-first OR3O™ Dual Mobility System utilising unique OXINIUM™ DH metal alloy for use in primary and revision hip arthroplasty
OXINIUM Technology is the first advanced bearing material available to support modular dual mobility throughout the entire offering LONDON , Nov. 8, 2019 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), ...
- Simply Wall St.
How Much Of Smith & Nephew plc (LON:SN.) Do Institutions Own?
The big shareholder groups in Smith & Nephew plc (LON:SN.) have power over the company. Generally speaking, as a...
- PR Newswire
Accelerate Diagnostics Appoints Roland Diggelmann to its Board of Directors
TUCSON, Ariz., Nov. 4, 2019 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX) today announced that Roland Diggelmann has been appointed to its Board of Directors. "On behalf of the entire board, I am delighted to welcome Roland to Accelerate Diagnostics," commented John Patience, Chairman of the Board of Directors. "Roland brings extensive experience from his decades of successful diagnostics company leadership.
- Reuters
U.S. patent board is unconstitutional, but problem can be fixed -appeals court
A federal appeals court on Thursday said the structure of the U.S. Patent Trial and Appeal Board is unconstitutional, but the problem can be fixed by severing a portion of federal patent law that restricts the removal of administrative patent judges. The U.S. Federal Circuit Court of Appeals said the impact of its decision would be "limited" to cases in which the board had issued final written decisions, and litigants challenged on appeal the appointment of the board's judges under the U.S. Constitution's Appointments Clause.
- Reuters
CORRECTED-UPDATE 2-European shares rise amid Brexit tussle as focus shifts to earnings
European shares broke a three-day run of losses on Monday, as investors stuck to hopes that Britain will avoid a disorderly exit from the European Union, while positive corporate updates and comments on U.S.-China trade talks added to the upbeat mood. The pan-European STOXX 600 index ended the session 0.6% higher, barely budging on news House of Commons speaker John Bercow refused to allow a vote on Prime Minister Boris Johnson's Brexit divorce deal, saying the same issue had been discussed on Saturday.
- Simply Wall St.
The Smith & Nephew (LON:SN.) Share Price Has Gained 86% And Shareholders Are Hoping For More
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses...
- Reuters
Ex-U.S. biotech executive fined for lying to auditors, charges dropped against CFO: SEC
The former chief business officer of U.S. biotechnology company Osiris Therapeutics Inc has agreed to pay a $40,000 civil penalty for lying to auditors, the Securities and Exchange Commission said on Thursday. The SEC had alleged that Bobby Dwayne Montgomery prompted Osiris to book fake revenue and give false information to auditors. Montgomery agreed to a judgment that enjoins him from future violations of securities law, the SEC said in a statement.
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Smith & Nephew plc (SNN)
We at Insider Monkey have gone over 730 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds' and investors' portfolio positions as of June 28th. In this article, we look at what those funds think of Smith & Nephew plc (NYSE:SNN) based on […]
